# Perioperative Pregabalin for Reducing Opioid Consumption After Cardiac Surgery

> **NCT04517110** · PHASE3 · TERMINATED · sponsor: **Hamilton Health Sciences Corporation** · enrollment: 17 (actual)

## Conditions studied

- Opioid Use

## Interventions

- **DRUG:** Pregabalin 300 mg
- **DRUG:** Pregabalin 75 mg
- **DRUG:** Pregabalin 300 mg Placebo
- **DRUG:** Pregabalin 75 mg Placebo
- **OTHER:** Usual Care

## Key facts

- **NCT ID:** NCT04517110
- **Lead sponsor:** Hamilton Health Sciences Corporation
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-09
- **Primary completion:** 2022-09-07
- **Final completion:** 2022-09-07
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** The COVID-19 pandemic has reduced recruitment such that the study is no longer feasible
- **Last updated:** 2022-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04517110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04517110, "Perioperative Pregabalin for Reducing Opioid Consumption After Cardiac Surgery". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04517110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*